MOTS-c FAERS Safety Signals: FDA Adverse Event Data and Regulatory Status

What Is MOTS-c and Why Does It Lack FAERS Data?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome's 12S rRNA gene. It was first characterized in 2015 by Lee et al. at the University of Southern California, who demonstrated that MOTS-c regulates metabolic homeostasis and insulin sensitivity in mice [1]. The peptide has since attracted interest for its potential roles in exercise physiology, aging, and glucose metabolism.

FAERS (the FDA Adverse Event Reporting System) collects voluntary reports of adverse drug reactions for FDA-approved and marketed products [2]. Because MOTS-c has never received FDA approval and is not commercially marketed as a pharmaceutical, it generates no FAERS signal. This absence does not mean the peptide is safe. It means the standard pharmacovigilance infrastructure does not apply.

A search of the FDA's Drugs@FDA database returns no results for MOTS-c. The FDA's FAERS public dashboard likewise shows zero case reports. The European Medicines Agency (EMA) has no European Public Assessment Report (EPAR) for MOTS-c, and the peptide does not appear in the EMA's EudraVigilance system [3].

The Difference Between "No Safety Signals" and "No Safety Data"

Zero FAERS reports might seem reassuring on the surface, but pharmacovigilance experts distinguish between a clean safety profile and an absent one. FAERS captures adverse events only when a product enters clinical use at scale. Products that have never been approved, prescribed, or dispensed through regulated channels simply do not generate the volume of exposure needed for signal detection.

The FDA's Sentinel System, which actively monitors claims data from over 100 million patients, also cannot detect MOTS-c signals because the peptide has no National Drug Code (NDC) and is not billed through pharmacy benefit managers [4]. This creates a blind spot. People who self-administer research-grade MOTS-c purchased from peptide vendors are not captured by any federal adverse event database.

For context, consider how FAERS works with approved peptides. Semaglutide (Ozempic, Wegovy) generated over 36,000 FAERS reports between 2018 and 2023 following widespread prescribing [5]. Tesamorelin, an FDA-approved growth hormone-releasing peptide, accumulated hundreds of FAERS entries after its 2010 approval for HIV-associated lipodystrophy [6]. MOTS-c has none of this infrastructure. No approval means no prescriptions, no pharmacy dispensing records, and no systematic adverse event capture.

Preclinical and Early Human Safety Observations

The published safety data on MOTS-c come almost entirely from animal models and limited human investigations. In the original 2015 study by Lee et al., mice treated with MOTS-c showed improved glucose tolerance without overt toxicity at the doses tested [1]. Subsequent murine studies have examined MOTS-c in the context of diet-induced obesity, skeletal muscle metabolism, and aging, generally reporting favorable metabolic effects without major adverse findings in short-duration protocols [7].

Human pharmacokinetic and safety data remain sparse. A 2024 review published in Peptides noted that MOTS-c concentrations decline with age and vary with exercise status, but acknowledged that no controlled human dose-escalation trial has established a maximum tolerated dose or characterized the peptide's full adverse event profile [8]. Without Phase I safety data in a peer-reviewed publication tied to an IND, the risk profile of exogenous MOTS-c administration in humans is essentially unknown territory.

One small study examined endogenous MOTS-c levels in humans during exercise and found that circulating concentrations rose acutely after physical activity, suggesting a physiological signaling role [9]. This observation, while interesting, does not inform the safety of supraphysiological dosing with synthetic MOTS-c.

Regulatory Classification: Where MOTS-c Sits Today

MOTS-c occupies a gray zone in the U.S. regulatory framework. It is not FDA-approved as a drug. It is not classified as a dietary supplement under DSHEA (the Dietary Supplement Health and Education Act of 1994), because peptides administered by injection do not qualify as supplements [10]. It is not listed on the FDA's Category 1, 2, or 3 bulk drug substance lists for compounding under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

The practical result: MOTS-c is sold primarily as a "research chemical" or "research peptide" by vendors who label their products "not for human consumption." This labeling sidesteps FDA enforcement but does not make human use legal or safe. The FDA has issued warning letters to peptide vendors selling other unapproved peptides (such as BPC-157 and thymosin beta-4) for similar regulatory violations [11]. No public warning letter specifically targeting MOTS-c vendors has been issued as of May 2026, but the legal framework is identical.

The Drug Enforcement Administration (DEA) has not scheduled MOTS-c. It does not appear on any state-level controlled substance lists. This means possession is not a criminal matter, but sale for human use without FDA approval remains a violation of federal drug law.

How Other Peptides Have Built FAERS Profiles

Comparing MOTS-c's regulatory vacuum to peptides that do have FAERS data is instructive. The trajectory from discovery to FAERS visibility typically follows a predictable path: preclinical work, IND filing, Phase I through III clinical trials, NDA/BLA submission, FDA approval, commercial launch, and then post-market surveillance.

Exenatide (Byetta), a glucagon-like peptide-1 receptor agonist derived from Gila monster venom, followed this path over roughly 13 years from initial characterization to FDA approval in 2005 [12]. By 2007, FAERS contained early signals for pancreatitis that prompted label updates and an FDA safety communication. Liraglutide (Victoza) accumulated thyroid C-cell tumor signals in FAERS that led to a boxed warning based on rodent carcinogenicity data [13].

These examples show how FAERS functions as an early warning system, but only for products that have cleared the regulatory threshold for market entry. MOTS-c has not begun this journey in any publicly documented way. No pharmaceutical company has announced clinical development programs for MOTS-c in ClinicalTrials.gov as of May 2026.

Risks of Using a Peptide With No Pharmacovigilance Coverage

The absence of FAERS data for MOTS-c creates specific risks for individuals who obtain and self-administer the peptide. Research-grade peptides sold online vary widely in purity. A 2023 analysis of peptides purchased from online vendors found that 38% of samples tested contained impurities, incorrect sequences, or bacterial endotoxins [14]. Without pharmaceutical-grade manufacturing (current Good Manufacturing Practice, or cGMP), each vial carries unknown contamination risk.

Beyond purity, the lack of established dosing protocols means users rely on anecdotal reports from online forums. No peer-reviewed publication has established a safe dose range for subcutaneous MOTS-c injection in humans. The endogenous circulating concentration of MOTS-c in healthy adults is measured in picomolar ranges [1]. Synthetic doses discussed in online communities (typically 5 to 10 mg administered several times per week) may exceed physiological levels by orders of magnitude. The consequences of this supraphysiological exposure over weeks or months are genuinely unknown.

If an adverse event does occur, the current reporting infrastructure may not capture it. MedWatch, the FDA's voluntary reporting portal, accepts reports for any product (including unapproved ones), but awareness and utilization of this system among self-administering peptide users is low [2]. Clinicians who encounter patients using MOTS-c may not recognize the peptide or know to file a MedWatch report, further reducing the likelihood that any signal would surface.

What Would Need to Happen for MOTS-c to Enter FAERS

For MOTS-c to generate meaningful FAERS data, a defined sequence of regulatory events would need to occur. First, a sponsor (pharmaceutical company, biotech firm, or academic institution) would need to file an IND application with the FDA, supported by preclinical toxicology data, chemistry/manufacturing/controls (CMC) documentation, and a proposed Phase I clinical protocol [15].

Phase I trials would establish basic pharmacokinetics, maximum tolerated dose, and acute safety in a small number of healthy volunteers. Phase II would explore efficacy signals and dose-response relationships. Phase III would require large, randomized, placebo-controlled trials powered to detect both efficacy and safety outcomes.

Only after NDA or BLA approval and commercial launch would FAERS begin accumulating real-world adverse event data. This full development cycle typically takes 10 to 15 years and costs an estimated $1.3 billion on average, according to a 2020 analysis published in JAMA [16]. For a naturally occurring mitochondrial peptide without strong patent protection, the commercial incentive to fund this development pathway is limited.

An alternative pathway could involve the FDA's 503B outsourcing facility framework, which allows compounding of bulk drug substances that appear on an approved list. BPC-157, another peptide of interest, was nominated for inclusion on this list but was ultimately not added after FDA review [11]. MOTS-c has not been formally nominated for 503B consideration.

Monitoring Your Own Safety Without FAERS

Individuals who choose to use MOTS-c despite the regulatory vacuum should establish a monitoring protocol with a licensed clinician. Baseline and follow-up laboratory panels should include fasting glucose, HbA1c, a comprehensive metabolic panel, complete blood count, and liver function tests. These markers can detect metabolic disruption, hepatotoxicity, or hematologic changes that might indicate an adverse response.

Any suspected adverse event should be reported directly to the FDA via MedWatch (online at fda.gov/medwatch) or by calling 1-800-FDA-1088 [2]. Voluntary reporting is the only mechanism that could begin building a FAERS profile for unapproved peptides, and individual reports do matter. The FDA has initiated safety reviews based on as few as a handful of MedWatch submissions when a pattern emerges.